ROS Regulation in CNS Disorder Therapy: Unveiling the Dual Roles of Nanomedicine DOI

Zhengyang Quan,

Sa Wang,

Huanhuan Xie

et al.

Small, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 15, 2024

Abstract The treatment of brain diseases has always been the focus attention. Due to presence blood‐brain barrier (BBB), most small molecule drugs are difficult reach brain, leading undesirable therapeutic outcomes. Recently, nanomedicines that can cross BBB and precisely target lesion sites have emerged as thrilling tools enhance early diagnosis treat various intractable disorders. Extensive research shown reactive oxygen species (ROS) play a crucial role in occurrence progression diseases, including tumors neurodegenerative (NDDs) such Alzheimer's disease, Parkinson's stroke, or traumatic injury, making ROS potential target. In this review, on structure function well mechanisms first elaborated through which nanomedicine traverses it. Then, recent studies production summarized photodynamic therapy (PDT), chemodynamic (CDT), sonodynamic (SDT) for treating tumors, depletion NDDs. This provides valuable guidance future design ROS‐targeted disease treatment. ongoing challenges perspectives developing nanomedicine‐based management also discussed outlined.

Language: Английский

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines DOI Creative Commons
Mohan Liu, Yusi Wang, Yi-Bing Zhang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: March 10, 2025

Abstract The ability of small nucleic acids to modulate gene expression via a range processes has been widely explored. Compared with conventional treatments, acid therapeutics have the potential achieve long-lasting or even curative effects editing. As result recent technological advances, efficient delivery for therapeutic and biomedical applications achieved, accelerating their clinical translation. Here, we review increasing number classes most common chemical modifications platforms. We also discuss key advances in design, development application each platform. Furthermore, this presents comprehensive profiles currently approved drugs, including 11 antisense oligonucleotides (ASOs), 2 aptamers 6 siRNA summarizing modifications, disease-specific mechanisms action strategies. Other candidates whose trial status recorded updated are discussed. consider strategic issues such as important safety considerations, novel vectors hurdles translating academic breakthroughs clinic. Small produced favorable results trials address previously “undruggable” targets, suggesting that they could be useful guiding additional candidates.

Language: Английский

Citations

1
Metal-phenolic networks specifically eliminate hypoxic tumors by instigating oxidative and proteotoxic stresses DOI
Jia Liu,

Zuoyu Chen,

Lixue Deng

et al.

Bioactive Materials, Journal Year: 2025, Volume and Issue: 47, P. 361 - 377

Published: Feb. 12, 2025

Language: Английский

Citations

0
In situ carrier-free nanovaccines reversing the immunosuppressive microenvironment for boosting tumor immunotherapy DOI
Yi‐Lei Zhao,

Guoxin Zhu,

Xuechun Wang

et al.

Chinese Chemical Letters, Journal Year: 2025, Volume and Issue: unknown, P. 111031 - 111031

Published: March 1, 2025

Language: Английский

Citations

0
A carrier-free DNA nanoplatform for efficient three-in-one tumor therapy in vivo DOI
Hong Wang,

Xuehe Lu,

Jing Fan

et al.

Nano Today, Journal Year: 2025, Volume and Issue: 62, P. 102734 - 102734

Published: March 27, 2025

Language: Английский

Citations

0
tert-Butoxycarbonyl-Modification Driven Disturbance of Molecular Ordering Enables High-Efficiency Dual Drugs Co-Assembly for Synergistic Tumor Inhibition DOI
Xuequan Zhang,

Xiaoxian Zhang,

Jiahui Zhu

et al.

ACS Nano, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

The development of carrier-free drug delivery systems (CDDS) for tailored combinations posed a significant challenge, particularly in achieving efficient co-assembly while maintaining therapeutic efficacy. Herein, we proposed strategy based on molecular engineering. Paclitaxel (PTX) and 7-ethyl-10-hydroxycamptothecin (SN38) were chemically modified with tert-butoxycarbonyl (BOC) groups. successful incorporation the BOC groups was confirmed by proton nuclear magnetic resonance mass spectrometry analyses. Further characterization using polarized light microscopy X-ray diffraction revealed that this modification significantly reduced crystallinity both drugs, simultaneously disrupting their original ordered stacking structure. Molecular dynamics simulations indicated increased spacing, density, expanded volume, resulting looser packing arrangement. This structural alteration enabled molecules to efficiently coassemble α-tocopherol succinate (α-TOS) into spherical nanoparticles at nearly predefined ratio. exhibited high loading capacity 52.66% remained stable 4 °C over 50 days. Notably, these displayed controllable release characteristics pH 5.0. Both vitro vivo studies demonstrated BOC-modified drugs retained bioactivity. When co-assembled α-TOS, synergistic antitumor effect suppressed tumor metastasis through downregulation matrix metalloproteinase-9 (MMP-9) expression. study provided solid theoretical foundation innovative approach CDDS, utilizing molecular-scale regulation co-assembly.

Language: Английский

Citations

0
Tactics to Improve the Photodynamic Therapeutic Efficacy Based on Nanomaterials DOI
Yinghao Cao, Xiaoping Qian,

Mengqi Shi

et al.

Chinese Journal of Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: April 19, 2025

Comprehensive Summary The development of photodynamic therapy (PDT), from its initial discovery effects to current use in various medical conditions, is a testament therapeutic potential. Recent breakthroughs nanotechnology have significantly enhanced the effectiveness PDT. Typical nanomaterials (NMs), including metal‐organic frameworks (MOFs), covalent organic (COFs), and nanozymes been introduced enhance efficacy because they can delivery PSs, effectively overcome insufficient targeting specificity, limited tissue penetration depth, hypoxic microenvironments, thereby amplifying efficacy. However, clinical application these NMs PDT faces several challenges, concerns regarding biocompatibility, long‐term biosafety, economic feasibility. To further advance PDT, researchers should focus on designing improve outcomes, exploring combination therapies with conducting translational trials validate safety novel approaches. This review summarizes recent progress based NMs, especially MOFs, COFs their disease treatment. We aim provide guidance for future research practice advancing NMs‐enhanced paving way more effective strategies. Key Scientists

Language: Английский

Citations

0
Nanometer preparation of natural bioactive compounds for treatment of rheumatoid arthritis DOI Creative Commons

Junping Zhu,

Xiang Qin, Qi Li

et al.

Journal of Pharmaceutical Analysis, Journal Year: 2025, Volume and Issue: unknown, P. 101341 - 101341

Published: May 1, 2025

Language: Английский

Citations

0
Multifunctional nanomaterials composed entirely of active pharmaceutical ingredients for synergistically enhanced antitumor and antibacterial effects DOI Creative Commons

Qi An,

Dongmei Wang, Liang Huang

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 21, 2024

Introduction Multifunctional nanomaterials are emerging as promising tools for treating both cancer and bacterial infections. However, integrating dual therapeutic capabilities into a single system remains challenging. This study presents multifunctional nanoparticles (ECI-NPs) based on Epigallocatechin gallate (EGCG) oligomers, Curcumin (CUR), Indocyanine Green (ICG) combined treatment. Methods ECI-NPs were synthesized via oxidative coupling of EGCG, CUR, ICG. The characterized stability, size, drug loading, release profiles. Cellular uptake, phototoxicity in melanoma cells, antibacterial activity against Escherichia coli Staphylococcus aureus also evaluated. Results demonstrated optimal high controlled release. studies showed increased uptake greater cells compared to free drugs. exhibited enhanced anticancer effects strong activity, outperforming the individual components. Discussion polyphenol-based offer synergistic effects, overcoming limitations drugs terms solubility efficacy. dual-function platform shows potential broader biomedical applications, addressing challenges Further research will focus vivo clinical translation.

Language: Английский

Citations

2
ROS Regulation in CNS Disorder Therapy: Unveiling the Dual Roles of Nanomedicine DOI

Zhengyang Quan,

Sa Wang,

Huanhuan Xie

et al.

Small, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 15, 2024

Abstract The treatment of brain diseases has always been the focus attention. Due to presence blood‐brain barrier (BBB), most small molecule drugs are difficult reach brain, leading undesirable therapeutic outcomes. Recently, nanomedicines that can cross BBB and precisely target lesion sites have emerged as thrilling tools enhance early diagnosis treat various intractable disorders. Extensive research shown reactive oxygen species (ROS) play a crucial role in occurrence progression diseases, including tumors neurodegenerative (NDDs) such Alzheimer's disease, Parkinson's stroke, or traumatic injury, making ROS potential target. In this review, on structure function well mechanisms first elaborated through which nanomedicine traverses it. Then, recent studies production summarized photodynamic therapy (PDT), chemodynamic (CDT), sonodynamic (SDT) for treating tumors, depletion NDDs. This provides valuable guidance future design ROS‐targeted disease treatment. ongoing challenges perspectives developing nanomedicine‐based management also discussed outlined.

Language: Английский

Citations

2